InVivoMab anti-mouse CD137 (4-1BB)

Catalog number: BE0239_100mg
Brand: Bio X Cell
Packing: 100 mg
Other sizes: Other sizes available
Price: € 2715.00
Expected delivery time: 7 days
Quantity:

Product specifications for - InVivoMab anti-mouse CD137 (4-1BB)

Promotion: 
Promotion: The price displayed is only for academic or non-profit organizations. Please contact our helpdesk for regular prices.
Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: Other Application
Species: Mouse
Host: Rat
Clonality: Monoclonal
Isotype: IgG2a
Properties: 
Molecular weight: 150 kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 2-10 mg/ml
Scientific information: 
Clone ID: 3H3
Related products: 
Related products: Recommended Isotype Control(s): InVivoMab rat IgG2a isotype control (BE0089)
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer (IP0070)
Additional information: 
Synonyms: 3H3; BE0239; BioXCell
Giardino torchia ML, Munitic I, Castro E, Herz J, Mcgavern DB, Ashwell JD. c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8(+) memory T-cell survival. Eur J Immunol. 2015;45(9):2672-82. Read more
Kobayashi T, Doff BL, Rearden RC, Leggatt GR, Mattarollo SR. NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology. 2015;4(3):e990793. Read more
Guillerey C, Ferrari de andrade L, Vuckovic S, et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest. 2015;125(5):2077-89. Read more
Tewalt EF, Cohen JN, Rouhani SJ, et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood. 2012;120(24):4772-82. Read more
Verbrugge I, Hagekyriakou J, Sharp LL, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012;72(13):3163-74. Read more
Vezys V, Penaloza-macmaster P, Barber DL, et al. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol. 2011;187(4):1634-42. Read more